New Three-Pronged attack on tough pancreatic tumors before surgery
NCT ID NCT07469956
Summary
This study is testing whether a combination of three types of drugs can help shrink tumors before surgery in people with high-risk or borderline operable pancreatic cancer. The treatment includes a targeted drug (surufatinib), an immunotherapy drug (toripalimab), and a standard chemotherapy regimen (mFOLFIRINOX). Researchers want to see if this approach helps more patients have successful surgery and live longer without the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.